Abstract

PURPOSE OF REVIEW: This article presents data about inflammatory myelopathies, also referred to as transverse myelitis. While the idiopathic form of this condition is rare, the prevalence of transverse myelitis is relatively common when including all of the secondary causes, such as multiple sclerosis (MS). Thus, clinicians and researchers should be familiar with the presentations, diagnostic algorithms, treatment options, and long-term symptom management for patients with transverse myelitis. This review presents data about the idiopathic and secondary forms of transverse myelitis.

RECENT FINDINGS: As research has expanded, the presentations of transverse myelitis have been clarified and the secondary causes explored. With the identification of the aquaporin-4 (AQP4) antibody, more patients with transverse myelitis have been categorized as having neuromyelitis optica (NMO), and more variable presentations have been published. A growing experience with various treatment options has expanded the therapeutic approaches to acute inflammatory myelopathies beyond standard corticosteroid intervention regimens.

SUMMARY: Transverse myelitis can occur in isolation or as part of a larger systemic condition. An empiric approach to patient evaluation can accelerate diagnosis of secondary conditions. Mounting evidence suggests that an aggressive approach to therapy can improve patient outcomes, but large-scale prospective trials are lacking.

Original languageEnglish (US)
Pages (from-to)121-131
Number of pages11
JournalContinuum (Minneapolis, Minn.)
Volume21
Issue number1 Spinal Cord Disorders
DOIs
StatePublished - Feb 1 2015

Fingerprint

Transverse Myelitis
Spinal Cord Diseases
Myelitis
Aquaporin 4
Neuromyelitis Optica
Therapeutics
Multiple Sclerosis
Adrenal Cortex Hormones
Research Personnel
Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Immune-mediated myelopathies. / Greenberg, Benjamin; Frohman, Elliot.

In: Continuum (Minneapolis, Minn.), Vol. 21, No. 1 Spinal Cord Disorders, 01.02.2015, p. 121-131.

Research output: Contribution to journalArticle

Greenberg, Benjamin ; Frohman, Elliot. / Immune-mediated myelopathies. In: Continuum (Minneapolis, Minn.). 2015 ; Vol. 21, No. 1 Spinal Cord Disorders. pp. 121-131.
@article{80c8670622ea4e27add8de9182a0695b,
title = "Immune-mediated myelopathies",
abstract = "PURPOSE OF REVIEW: This article presents data about inflammatory myelopathies, also referred to as transverse myelitis. While the idiopathic form of this condition is rare, the prevalence of transverse myelitis is relatively common when including all of the secondary causes, such as multiple sclerosis (MS). Thus, clinicians and researchers should be familiar with the presentations, diagnostic algorithms, treatment options, and long-term symptom management for patients with transverse myelitis. This review presents data about the idiopathic and secondary forms of transverse myelitis.RECENT FINDINGS: As research has expanded, the presentations of transverse myelitis have been clarified and the secondary causes explored. With the identification of the aquaporin-4 (AQP4) antibody, more patients with transverse myelitis have been categorized as having neuromyelitis optica (NMO), and more variable presentations have been published. A growing experience with various treatment options has expanded the therapeutic approaches to acute inflammatory myelopathies beyond standard corticosteroid intervention regimens.SUMMARY: Transverse myelitis can occur in isolation or as part of a larger systemic condition. An empiric approach to patient evaluation can accelerate diagnosis of secondary conditions. Mounting evidence suggests that an aggressive approach to therapy can improve patient outcomes, but large-scale prospective trials are lacking.",
author = "Benjamin Greenberg and Elliot Frohman",
year = "2015",
month = "2",
day = "1",
doi = "10.1212/01.CON.0000461088.63994.a2",
language = "English (US)",
volume = "21",
pages = "121--131",
journal = "CONTINUUM Lifelong Learning in Neurology",
issn = "1080-2371",
publisher = "Lippincott Williams and Wilkins",
number = "1 Spinal Cord Disorders",

}

TY - JOUR

T1 - Immune-mediated myelopathies

AU - Greenberg, Benjamin

AU - Frohman, Elliot

PY - 2015/2/1

Y1 - 2015/2/1

N2 - PURPOSE OF REVIEW: This article presents data about inflammatory myelopathies, also referred to as transverse myelitis. While the idiopathic form of this condition is rare, the prevalence of transverse myelitis is relatively common when including all of the secondary causes, such as multiple sclerosis (MS). Thus, clinicians and researchers should be familiar with the presentations, diagnostic algorithms, treatment options, and long-term symptom management for patients with transverse myelitis. This review presents data about the idiopathic and secondary forms of transverse myelitis.RECENT FINDINGS: As research has expanded, the presentations of transverse myelitis have been clarified and the secondary causes explored. With the identification of the aquaporin-4 (AQP4) antibody, more patients with transverse myelitis have been categorized as having neuromyelitis optica (NMO), and more variable presentations have been published. A growing experience with various treatment options has expanded the therapeutic approaches to acute inflammatory myelopathies beyond standard corticosteroid intervention regimens.SUMMARY: Transverse myelitis can occur in isolation or as part of a larger systemic condition. An empiric approach to patient evaluation can accelerate diagnosis of secondary conditions. Mounting evidence suggests that an aggressive approach to therapy can improve patient outcomes, but large-scale prospective trials are lacking.

AB - PURPOSE OF REVIEW: This article presents data about inflammatory myelopathies, also referred to as transverse myelitis. While the idiopathic form of this condition is rare, the prevalence of transverse myelitis is relatively common when including all of the secondary causes, such as multiple sclerosis (MS). Thus, clinicians and researchers should be familiar with the presentations, diagnostic algorithms, treatment options, and long-term symptom management for patients with transverse myelitis. This review presents data about the idiopathic and secondary forms of transverse myelitis.RECENT FINDINGS: As research has expanded, the presentations of transverse myelitis have been clarified and the secondary causes explored. With the identification of the aquaporin-4 (AQP4) antibody, more patients with transverse myelitis have been categorized as having neuromyelitis optica (NMO), and more variable presentations have been published. A growing experience with various treatment options has expanded the therapeutic approaches to acute inflammatory myelopathies beyond standard corticosteroid intervention regimens.SUMMARY: Transverse myelitis can occur in isolation or as part of a larger systemic condition. An empiric approach to patient evaluation can accelerate diagnosis of secondary conditions. Mounting evidence suggests that an aggressive approach to therapy can improve patient outcomes, but large-scale prospective trials are lacking.

UR - http://www.scopus.com/inward/record.url?scp=84942414656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942414656&partnerID=8YFLogxK

U2 - 10.1212/01.CON.0000461088.63994.a2

DO - 10.1212/01.CON.0000461088.63994.a2

M3 - Article

C2 - 25651221

AN - SCOPUS:84923204885

VL - 21

SP - 121

EP - 131

JO - CONTINUUM Lifelong Learning in Neurology

JF - CONTINUUM Lifelong Learning in Neurology

SN - 1080-2371

IS - 1 Spinal Cord Disorders

ER -